Pharmaceutical

argenx’s VYVDURA gains approval in Japan for gMG treatment

Japan has approved argenx’s VYVDURA injection for subcutaneous administration to treat generalised myasthenia gravis (gMG) in adults.

Jan 19, 2024 - 18:00
argenx’s VYVDURA gains approval in Japan for gMG treatment
Japan has approved argenx’s VYVDURA injection for subcutaneous administration to treat generalised myasthenia gravis (gMG) in adults.
Read the original article

Tags:

Previous Article

BridgeBio secures $1.25bn for genetic therapy development

Next Article

Synendos set to study endocannabinoid inhibitor for neuropsychiatric conditions

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Study suggests Covid rebound is far more common with Paxlovid than without

Study suggests Covid rebound is far more common with Pa...

Nov 13, 2023

FDA approves Galderma’s Nemluvio to treat atopic dermatitis

FDA approves Galderma’s Nemluvio to treat atopic dermat...

Dec 17, 2024

STAT+: Health care CEOs hauled in $4 billion last year as inflation pinched workers, analysis shows

STAT+: Health care CEOs hauled in $4 billion last year ...

Aug 17, 2023